He fled Apartheid South Africa at 25. Then he built a $13 billion Fortune 500 company. Here are his rules

Henry Schein reports $13.2B in annual revenue; CEO Stanley Bergman retired after 36 years and was succeeded by Fred Lowery on March 2. Bergman scaled the company from $225M to $13.2B through acquisitions, global expansion, joint ventures and distribution decentralization while emphasizing values-driven leadership and philanthropy (e.g., 'Give Kids a Smile' serves >300,000 children annually). The board executed an independent succession process to ensure a smooth transition and operational stability; the company is No. 333 on the Fortune 500.

Analysis

A leadership handoff at a large, platform-style healthcare distributor materially changes the risk profile: a deliberate pause in dealmaking typically reduces near-term execution risk and frees up cash flow to drive margin through integration, SKU rationalization and logistics optimization. Markets tend to underwrite roll-ups at a discount until the integration scorecard is visible; if management shifts from growth-by-acquisition to consolidation, multiples can re-rate within 6–12 months as normalized free cash flow becomes more predictable.

Operational playbooks from big healthcare distributors emphasize SKU rationalization, pricing discipline and paid-services attach (repairs, software subscriptions, consulting) — these actions expand gross margin 100–300 bps over 12–24 months if implemented cleanly, but they also compress margin for small regional distributors and entrepreneurial JV partners who depend on looser commercial terms. Expect second-order supply-chain moves: decentralization of critical SKUs to regional hubs reduces service lead times but raises working capital; a reversal or acceleration of that policy will swing NWC by several hundred million at scale over a 12–18 month horizon.

Key risks are cultural pushback and customer churn from heavy-handed centralization, and macro sensitivity in elective clinical spend (dental/ambulatory) which can cut revenue visibility in a recessionary window of 3–9 months. A governance-driven successor with a background in large-scale distribution typically triggers a two-phase outcome: first, cost and process initiatives that lift EBITDA margin; second, selective bolt-on M&A to fill service or geographic gaps — both phases present tradable inflection points for equity and options strategies.

Key Decisions for Investors

• Long HSIC equity (6–12 month horizon): size 3–5% of portfolio. Rationale: consolidation-focused playbooks should de-risk free cash flow and drive a 15–30% total-return rerating if integration efficiencies and service-attach growth materialize. Use a 10% stop-loss and take profits in tranches at 15% and 30%.
• Pair trade — Long HSIC / Short PDCO (6–12 months): size net-neutral 2–4% exposure. Rationale: HSIC’s scale and potential for higher-margin services make it a better candidate for multiple expansion versus regionally concentrated competitors; target spread tightening of 15–25%. Risk: narrow dental macro weakness that hurts both names.
• Buy HSIC 9–12 month call spread (slightly OTM): allocate 1–2% of book to options to asymmetrically capture multiple expansion. Structure to cap premium outlay and aim for 3:1 upside/downside payoff if the market re-rates on clearer margin guidance.
• Selective long TMO on dips (12–24 months), small position 1–2%: rationale is optionality — if execution-focused leadership pursues cross-sector M&A or accelerates distribution best practices, large diversified healthcare distributors can capture share and reprice. Treat as satellite; downside limited to position size.